Skip to main content

Table 1 Baseline characteristics of BPC3 participants by cohort

From: A comprehensive analysis of the androgen receptor gene and risk of breast cancer: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)

 

ACS

EPIC

MEC

NHS

WHS

All

 

Cases

Controls

Cases

Controls

Cases

Controls

Cases

Controls

Cases

Controls

Cases

Controls

Number

503

505

1,719

2,844

1,617

1,962

1,059

1,464

705

705

5,603

7,480

Mean age in years at blood donation (standard deviation)

68.9 (5.9)

68.9 (5.8)

55.4 (7.9)

55.1 (8.3)

66.4 (8.6)

63.6 (8.7)

57.6 (7.0)

58.2 (6.9)

56.0 (7.3)

56.0 (7.3)

60.2 (9.4)

59.0 (9.0)

Mean body mass index (standard deviation)

25.2 (4.6)

25.5 (4.6)

25.9 (4.4)

26.1 (4.6)

26.7 (5.6)

27.0 (6.0)

25.4 (4.7)

25.6 (4.7)

25.5 (4.4)

26.0 (5.1)

25.9 (4.9)

26.2 (5.1)

Age in years at menarche

            

≤12

46.9

45.3

35.5

36.2

53.9

49.7

42.4

48.7

56.7

51.6

47.8

44.3

13–14

43.9

46.7

48.5

45.5

35.5

38.6

39.5

42.9

37.0

42.7

41.1

43.0

15+

9.3

8.0

16.0

18.4

10.5

11.7

8.1

8.4

6.2

5.7

11.0

12.7

Menopausal status

            

Premenopausal

0

0

24.3

27.7

11.0

16.5

19.4

16.9

21.7

21.2

17.0

20.2

Postmenopausal

100

100

67.1

63.6

86.5

81.8

71.3

74.8

63.5

60.2

76.0

72.7

Perimenopausal/unknown

0

0

8.6

8.7

2.5

1.7

9.4

8.3

14.8

18.6

7.0

7.1

Age in years at menopause*

            

<40

10.2

9.9

4.5

5.0

16.3

18.9

9.9

11.1

7.1

9.0

10.6

11.4

40–44

10.2

12.4

9.5

10.3

14.9

16.9

12.2

11.3

10.0

14.5

12.0

13.1

45–49

20.4

28.2

28.9

31.8

26.6

27.9

27.6

28.1

31.1

31.6

27.0

29.4

50–54

46.6

39.7

47.1

44.0

32.8

29.0

44.5

43.7

43.9

36.8

41.3

38.4

55+

12.6

9.9

10.0

8.9

9.4

7.3

5.8

5.8

7.8

8.0

9.1

7.8

Parous women

91.0

91.4

86.7

86.8

85.5

88.8

92.3

93.3

84.8

86.2

87.5

88.9

Family history

20.7

15.5

-

-

17.1

11.1

19.2

13.9

20.1

16.3

18.6

13.3

Ever HRT use*

67.0

58.7

42.3

34.1

63.9

58.9

77.2

72.0

68.0

60.3

61.4

53.5

Carcinoma in situ

21.5

-

6.3

-

1.0

-

0

-

0

-

4.1

-

ER-positive

52.7

-

-

-

62.0

-

68.0

-

80.4

-

65.8

-

PR-positive

44.5

-

-

-

51.1

-

57.5

-

71.9

-

55.8

-

Ethnicity

            

White

97.8

98.6

100

100

24.8

22.4

93.6

93.6

95.6

95.6

76.3

77.9

Hispanic

0.8

0.2

0

0

20.8

19.7

0.1

0.3

0.6

0.6

6.2

5.3

African-American

0.8

0.8

0

0

21.3

21.7

0.8

0.6

0.7

0.7

6.5

5.9

Asian

0.4

0.4

0

0

26.3

21.4

0.1

0.4

1.0

1.0

7.8

5.8

Hawaiian

0

0

0

0

6.7

14.8

0

0

0

0

2.0

3.9

Other

0.2

0

0

0

0

0

5.5

5.1

2.1

2.1

1.3

1.2

  1. ACS, American Cancer Society; BPC3, Breast and Prostate Cancer Cohort Consortium; EPIC, European Prospective Investigation into Cancer and Nutrition; ER, oestrogen receptor; HRT, hormone replacement therapy; MEC, Multiethnic Cohort; NHS, Nurses' Health Study; PR, progesterone receptor; WHS, Women's Health Study.
  2. * Among post-menopausal women only